Candesartan cilexetil 32 MG TB 90S
Ended Awarded Last action
- Contract number
- SPE2DR26FM44G
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $47,990
Award facts
- Contract value 100% obligated
- $47,989.79 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerSourceBergen Drug Corp on January 21, 2026, for the supply of Candesartan Cilexetil 32 mg tablets (90-count bottles) with a ceiling value of $47,989.79. The contract is a firm fixed-price delivery order with an ultimate completion date of January 22, 2026, and was competitively awarded with no set-aside designation. AmerSourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with Cencora, Inc. (doing business as AmerSourceBergen) operating as its parent organization. This delivery order falls under the broader Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical, a $999.99 billion contract through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare systems globally.
Candesartan Cilexetil is an antihypertensive medication used in military and veteran healthcare settings to manage hypertension and support cardiovascular health across the Defense Health Agency and other federal medical institutions. AmerSourceBergen's extensive portfolio of federal pharmaceutical contracts demonstrates its critical role as a primary vendor in the federal medical supply chain. The company's federal contracting experience encompasses a diverse range of therapeutic categories including diabetes medications, neurological treatments, pain management pharmaceuticals, and specialized medical supplies, positioning it as a reliable supplier for the DLA's ongoing medical procurement requirements.
Quick answers
Who was awarded contract SPE2DR26FM44G?
SPE2DR26FM44G was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FM44G worth?
The government has obligated $47,990 on SPE2DR26FM44G.
Is contract SPE2DR26FM44G an order under another contract?
Yes. SPE2DR26FM44G is a delivery order under SPE2DR25D2007, an indefinite delivery contract.
Was contract SPE2DR26FM44G competed?
The extent of competition for SPE2DR26FM44G was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award